Outset Medical Inc. (OM) Misses Q2 EPS by 13c

Outset Medical Inc. (OM) to Resume Trading at 10:30 a.m.

Outset Medical Inc. (NASDAQ: OM) to Resume Trading at 10:30 a.m.

Outset Medical (OM) Resumes Shipment of Tablo Systems for Home Use, Reports Second Quarter 2022 Financial Results and Provides 2022 Guidance

Outset Medical, Inc. (Nasdaq: OM) (Outset or the Company), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced clearance by the Food and Drug Administration of its previously disclosed 510(k) submission and resumption of Tablo® Hemodialysis System shipments for home use.

The Company also reported financial results for the second quarter ended June 30, 2022 and provided financial guidance for 2022. Revenue for the second quarter totaled $25.1 million, in line with guidance provided on June 13, 2022. Gross margin for the second quarter was 15.1%, compared to 4.2% in the second... More

Outset Medical Inc. (OM) Halted, News Pending

Outset Medical Inc. (NASDAQ: OM) Halted, News Pending

Cowen Reiterates Outperform Rating on Outset Medical Inc. (OM), Comments on FDA Clearance

Cowen analyst Joshua Jennings reiterated an Outperform rating and $33.00 price target on Outset Medical Inc. (NASDAQ: OM).

The analyst comments "OM Has Received a New 510(k) Clearance for the Tablo Hemodialysis System. In a decision dated July 29, 2022, the FDA cleared a new 510(k)... More

Stifel on Outset Medical Inc. (OM): 'At Last, A Big Sigh of Relief As FDA Terms Tablo Catch-Up Filing As “Substantially-Equivalent”'

Stifel analyst Rick Wise reiterated a Buy rating and $24.00 price target on Outset Medical Inc. (NASDAQ: OM).

The analyst comments "Last Friday, Outset received a positive FDA update on its Tablo catch-up 510K filing, with the agency providing a substantially-equivalent decision on the filing.... More